Table 3 c-kit expression in lymphoid malignancies
From: Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
Type of lymphoma | Methods | Positive c-kit expression/N (%) | References |
|---|---|---|---|
Multiple myeloma | Flow cytometry | 49/158 (31%) | Kraj 2004 |
Multiple myeloma | Flow cytometry | 17/48 (35%) | Li 2004 |
Multiple myeloma | Flow cytometry | 18/56 (32%) | Ocqueteau 1996 |
Multiple myeloma | Immunohistochemistry | 5/31 (16%) | Potti 2002 |
Multiple myeloma | Immunohistochemistry | 2/72 (3%) | Lugli 2004 |
Cutaneous plasmacytoma | Immunohistochemistry | 13/13 (100%) | Bayer-Garner 2003 |
Total MM | / | 104/378 (27%) | / |
Lymphoplasmacytic | Immunohistochemistry | 0/10 (0%) | Lugli 2004 |
Lymphoplasmacytic | Flow cytometry | 0/7 (0%) | Kraj 2004 |
Mantle cell L. | Immunohistochemistry | 2/17 (1%) | Potti 2002 |
Lymphomatoid papulosis | Immunohistochemistry | 0/18 (0%) | Rassidakis 2004 |
DLBCL | Immunohistochemistry | 24/65 (37%) | Vakiani 2005 |
Total B-cell L. | / | 26/117 (22%) | / |
CD30+ anaplastic large cell L. | Immunohistochemistry | 7/18 (39%) | Brauns 2004 |
CD30+ anaplastic large cell L. | Immunohistochemistry | 11/16 (69%) | Pinto 1994 |
CD30+ anaplastic large cell L. | Immunohistochemistry | 1/78 (1%) | Rassidakis 2004 |
Lymphomatoid papulosis | Immunohistochemistry | 0/18 (0%) | Rassidakis 2004 |
Total CD30+ L. | / | 19/130 (15%) | / |
Nasal NK/T-cell L. | Immunohistochemistry | 0/36 (0%) | Li 2006 |
Cutaneous T-cell L. | Immunohistochemistry | 2/8 (25%) | Brauns 2004 |
Mycosis fungoides | Immunohistochemistry | 6/18 (33%) | Brauns 2004 |
Sezary's syndrome | Immunohistochemistry | 3/5 (60%) | Brauns 2004 |
Total T-cell L. | / | 11/67 (16%) | / |
Hodgkin's disease | Immunohistochemistry | 11/21 (52%) | Pinto 1994 |
Hodgkin's disease | Immunohistochemistry | 0/87 (0%) | Rassidakis 2004 |
Hodgkin's disease | Immunohistochemistry | 0/342 (0%) | Zimpfer 2004 |
Total HD | / | 11/450 (2%) | / |